
1,491,140 (100%)
NCDB PCa, 2004-2016
413,178 (27.27%)
T3-T4, N+, M1
1,077,962 (72.3%)
Stage T1-T2N0M0
142,225 (11.5%)
Non-invasive or other malignant neoplasm
934,764 (60.8%)
Invasive histology, single primary, Grade 1-3
94,939 (6.4%)
No biopsy or other surgical procedure
811,881 (54.4%)
Biopsy performed
27,909 (1.9%)
Treatment not performed at reporting facility
783,972 (52.6%)
Treatment at reporting facility
228,488 (15.3%)
PSA > 20 or not available
Gleason score > 7
555,484 (37.3%)
PSA > 0 and PSA ≤ 20
Gleason score 6 or 7
231,138 (15.5%)
Low or high risk
324,346 (21.8%)
Intermediate risk factors:
Gleason 3+4 or 4+3,
PSA≥10, or clinical stage
T2b/T2c
203,219 (13.7%)
Surgery, active surveillance, or other radiation treatment
121,127 (8.1%)
Beam radiation, radioactive implants, or combined beam with implants
10,076 (0.7%)
Hormone therapy contraindicated, refused or unknown
111,051 (7.4%)
Hormone treatment data available
2,866 (0.2%)
Missing demographic/facility data
108,185 (7.3%)
Complete demographic data